Sp756

MECHANISM OF ROS-INDUCED BARRIER DYSFUNCTION

Date
May 8, 2023
Explore related products in the following collection:

Society: AGA

Reactive oxygen species (ROS) are by-products of normal cellular metabolism with low to moderate amounts being beneficial in several physiological processes in the intestine. Chemotherapy and radiotherapies are largely based upon ROS generation to destroy malignant cells by inducing apoptosis. Nonetheless, disproportionate generation of ROS causes oxidative tissue damage and development of a range of gut disorders including inflammatory bowel diseases. Considering the role of oxidative stress in IBD, implementation of antioxidant therapy such as 5-aminosalicylic acid has been commonly used in patients. However, given the challenges in antioxidant therapies in IBD including effectiveness and interference with normal redox signaling, there is a dire need to develop efficient and targeted therapies. Thus, there has been a growing interest in understanding the metabolic precursors of ROS, their effects on host intestinal epithelium as well as implications in diseases including intestinal inflammation. This basic and translational symposium aims to bring together various aspects of redox signaling ranging from role of ROS in modulating intestinal barrier function, role of mitochondria and ER in epithelial cell lineages and discussing the role of microbiota in intestinal oxidative stress. In addition, the experts in the field will be discussing the mechanisms pertinent to protect intestinal epithelium from oxidative insult and illuminate the current landscape and prospectives on redox targeted therapeutics for GI diseases.

Presenter

Speaker Image for Radhakrishna (Rk) Rao
University of Tennessee

Tracks

Related Products

Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…